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Guermarie Velázquez-Torres, Ph.D.
Supervisor Professor: Mong-Hong Lee, Ph.D.
ABSTRACT
Pancreatic cancer is one of the most aggressive types of cancer, with poor
prognosis that lacks effective diagnostic markers and therapies. It is expected
that in 2014 the incidence and the mortality of pancreatic cancer in the United
States will be 46,420 and 39,590 respectively. Diabetes and obesity are
modifiable risk factors associated with accelerated pancreatic carcinogenesis
and tumor progression, but the biological mechanisms are not completely
understood. The purpose of this study is to demonstrate direct evidence for the
mechanisms mediating these epidemiologic phenomena. Our hypothesis is that
obesity and diabetes mellitus type 2 (DM2) accelerate pancreatic cancer and that
metformin treatment has a beneficial impact. To determine the effect of glucose,
insulin and adipocytes in pancreatic cancer proliferation we used conditioned
media to mimic DM2 and obese conditions. Also, we studied the effect of antidiabetic drugs, particularly metformin and rosiglitazone on pancreatic cancer.
We established orthotopic/syngeneic mouse models to evaluate the effect of
obesity (Ay/a) and diabetes (Leprdb/Leprdb) on pancreatic tumor growth and
aggressiveness. Our results showed that both obesity and diabetes promote
pancreatic tumor growth. Furthermore, enhanced tumor growth and
aggressiveness (e.g., EMT) was explained by functional transcriptomic and
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metabolomic changes in the mice with obesity and diabetes, namely via
activation of the AKT/mTOR pathway. Metformin treatment decreased the
obesity-induced and diabetes-induced AKT/mTOR pathway activation and tumor
growth. Adipokine profile array showed an induced secretion of several
adipokines in the obese and diabetic mice compared with lean mice. Our coculture system showed a direct impact of adipocytes on the growth of pancreatic
cancer cells. In conclusion, obesity and diabetes have adverse effects that
promote pancreatic cancer progression by enhancing proliferation and
aggressiveness via transcriptomic and metabolomic changes. Adipocytes affect
tumor microenvironment and cancer cell proliferation through the secretion of
adipokines targeting cancer cells’ survival and proliferation. Our animal models
provide strong evidence for the causal relationship between obesity, diabetes
and accelerated pancreatic cancers. This study sheds a new insight of the effects
of metformin and its potential as part of therapeutic interventions for pancreatic
cancer in obese/diabetic patients.
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Chapter 1. Introduction
1.1 Pancreatic cancer
Pancreatic cancer has an annual worldwide incidence of more than 300,000
cases per year, it is among the top ten causes of cancer death worldwide (Li et
al., 2012; Parkin et al., 2005), and remains fourth cancer-related cause of death
in the United States (Maitra and Hruban, 2008). Pancreatic cancer is one of the
most aggressive malignancies with a five-year survival rate of approximately 5%.
The pancreas is an organ that possesses endocrine and gastric or exocrine
functions. Its endocrine role includes the production of protein hormones such as
insulin, glucagon, somatostatin, and pancreatic polypeptide that are secreted by
the alpha, beta, delta and gamma cells of the Langerhans islets, respectively. In
addition, the pancreas produces pancreatic juice important for the digestion of
carbohydrates, proteins, and lipids. The types of malignancies that affect the
pancreas mainly arise from exocrine component with pancreatic ductal
adenocarcinoma (PDAC) the most common malignancy in the pancreas.

1.1.1 Pancreatic cancer mouse models
PDX-1 and P48 are constitutively expressed transcription factors
important for the pancreas development (Kawaguchi et al., 2002; Offield et al.,
1996), which promoters were used to conditionally express KRAS G12D
transgene in the pancreas of mouse at embryonic stage (Hingorani et al., 2003).
These mouse models express the pancreatic intraneoplasia (PanIN) stages
	
  

1	
  
	
  

believed to be precursors of pancreatic cancer but very low percent of mice
develop the pancreatic ductal adenocarcinoma. In order to have the progression
of pancreatic cancer, it requires additional mutations in tumor suppressor genes
(e.g. TP53, P16/cdkn2A) (Perez-Mancera et al., 2012) that are known precursor
lesions (Hruban et al., 2000) occurring in PDAC. Recently the development of
inducible mouse models provide the advantage of controlling the expression of
mutant KRAS (Gidekel Friedlander et al., 2009; Ying et al., 2012).
In this research work, we studied pancreatic cancer in the context of
obesity and diabetes. For this reason we used obese and DM2
orthotopic/syngeneic mouse models using PancO2 mouse pancreatic cell line
(Corbett et al., 1984). This cell line was previously shown to be resistant to
almost all of the chemotherapeutic agents tested (Corbett et al., 1984)
representing an excellent model to study pancreatic cancer.

1.2 Diabetes mellitus type 2
Many epidemiological studies suggest the important role of diabetes mellitus
type 2 (DM2) in carcinogenesis (Coughlin et al., 2004; Muti et al., 2002; Nilsen
and Vatten, 2001; Richardson and Pollack, 2005; Verlato et al., 2003; Yamagata
et al., 2005), cancer survival (van de Poll-Franse et al., 2007), and as a
significant risk factor for pancreatic cancer (Ansary-Moghaddam et al., 2006; Lu
et al., 2006). Moreover, pancreatic cancer is associated with DM2 (Ben et al.,
2011; Everhart and Wright, 1995; Fisher, 2001; Kuriki et al., 2007; Lu et al.,
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2006; Stolzenberg-Solomon et al., 2005) and approximately 80% of pancreatic
cancer patients have DM2 (Permert et al., 1993).
DM2 has been associated with pancreatic cancer, but there is no clear
answer of which one comes first. There are two possibilities: pancreatic cancer
promotes DM2 or DM2 leads to pancreatic cancer carcinogenesis (Wang et al.,
2003). Literature support both hypotheses (Wang et al., 2003) and it is possible
that they are not exclusive between them. If DM2 results from pancreatic cancer,
it is possible for DM2 to have a positive feedback in promoting carcinogenesis
and cancer progression. On the other hand if diabetes comes first, then
pancreatic cancer can be viewed as an aggravation of DM2 (Everhart and
Wright, 1995). However, more studies are needed to confirm diabetes as a risk
factor for pancreatic cancer (Pezzilli and Pagano, 2013). Therefore, optimal
treatment of DM2 may play a major role in the primary prevention of pancreatic
cancer in diabetics.
Different drugs are used for diabetes treatment and these drugs have diverse
mechanisms of action and targets. The pharmacotherapy for diabetes includes:
insulin/insulin analogs, sulfunylureas, meglitinides, alpha glucosidase inhibitors,
thiazolidinediones, biguanides, incretin mimetics, DDP-4 inhibitors and amylin
analogs. Treatments of DM2 have different effects on insulin and IGF-1 signaling
and some of these treatments might be useful to prevent pancreatic cancer. In
this research study we focused on the study of the biguanide drug, metformin but
we also used other drugs as rosiglitazone/pioglitazone and excenatide. As it has
been previously reported, metformin activates AMPK (Jackson et al., 2001).
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Metformin improves glycemic control by decreasing intestinal absorption of
glucose and improving insulin sensitivity in muscle and liver tissue (Ota et al.,
2009). Another drug of interest are the thiazolidinediones
rosiglitazone/pioglitazone known to activate PPAR-γ (Teresi et al., 2006).
Rosiglitazone reduced lipid availability, improves insulin action and glucoregulation (Oakes, M.D. 1994). Excenatide is a glucagon like peptide-1 receptor
agonist, an incretin mimetic (Pi-Sunyer, 2008).

1.2.1 Diabetes mellitus type 2 mouse model
For the purpose of this study we used the diabetes mouse model Leprdb/db.
The leptin receptor gene in this mouse model contains a point mutation that
results in a stop codon that shortens the intracellular domain and abolishes its
signaling capacity (Koenig and Cerami, 1975). In order to express the disease it
is necessary to have homozygous Leprdb/Leprdb (db/db), which is a common
mouse model of DM2.
The expected median survival of the homozygous db/db mice is 13.3 months
(Barouch et al., 2006). At the age of two weeks old db/db mice start to show high
levels of insulin and at 5 weeks old these mice start to show high glucose levels
(Koenig and Cerami, 1975). Around the age of 3 to 4 weeks, these mice become
obese but with normal glucose levels (Koenig and Cerami, 1975). Then at the
age of 7 to 8 weeks of age these mice are considered obese, with high glucose,
insulin, and glucagon. It is not until 12 – 20 weeks of age when the insulin levels
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in these mice decrease toward normal (Roesler et al., 1990), similar to what
occur in diabetic patients.

1.3 Obesity
The World Health Organization (WHO) defines obesity as “abnormal or
excessive fat accumulation that presents a risk to health”. The body mass index
(kg/m2) is used to classify individuals as underweight, normal, overweight, and
obese (Table 1.3). Obesity is an increasing health issue that is an ongoing
pandemic problem affecting millions of people all over the World (James, 2008).
Obesity is also linked to DM2 (Hossain et al., 2007). Currently, more than the
35% of both adult men and women are obese in the US (Flegal et al., 2012).
Unfortunately, obesity is a modifiable risk factor associated with accelerated
pancreatic cancer progression and shorter survival (Ansary-Moghaddam et al.,
2006) and also related to other cancer types (Reeves et al., 2007).
Epidemiological studies strongly suggest a correlation between obesity and
pancreatic cancer, but little is known about the possible biological mechanisms
by which obesity promotes the pancreatic tumor growth, aggressive progression
and drug resistance. The promotion of pancreatic cancer by obesity may be
explained by hyperglycemia and deregulated adipokines secretion by adipocytes.
However, an important emerging cancer hallmark is the reprogramming of cancer
cells metabolic profile for survival, proliferation, invasion, metastasis and drug
resistance (Hanahan and Weinberg, 2011).

Some research groups have

described the involvement of the PI3K/AKT signaling pathway on pancreatic
	
  

5	
  
	
  

cancer cell proliferation, motility and migration (Perugini et al., 2000; Teranishi et
al., 2009). Thus, in order to further understand the underlying mechanisms of
obesity-induced pancreatic cancer, we need to determine the signaling pathways
related to these effects.
One of the most recent FDA approved drugs for obesity is Orlistat. Orlistat
inhibit GI lipases and block or prevent the absorption of about 30% of dietary fat
(Pi-Sunyer F.X. 2008). For this study we tested orlistat effect in cell proliferation
and glucose uptake.

Table 1.3: Adult Body Mass Index Classification

Body Mass Index classification
Underweight
<18.5
Normal Range
18.5-24.9
Overweight:
≥25.0
Pre-obese
25.0-29.9
Obese:
≥ 30.0
Obese Class I
30-34.9
Obese Class II
35.0-39.9
Obese Class III
≥40
Adapted from World Health Organization:
(http://www.who.int/dietphysicalactivity/childhood_what/en/)

1.3.1 Obese mouse model
Among several mouse models for obesity, the agouti gene mutants have
been extensively studied (Chua, 1997; Robinson et al., 2000; Walkley et al.,
1978). In mammals, the agouti gene (a) encodes a paracrine protein factor (131	
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amino-acid protein), which antagonize melanocortin-1 receptor (Mc1r), αmelanocyte-stimulating hormone (α-MSH) receptor, melanocortin-3 receptor
(Mc3r) and melanocortin-4 receptor (Mc4r) (Eberle et al., 2001; Kiefer et al.,
1997; Lu et al., 1994; Ollmann et al., 1998; Yen et al., 1994). The agouti gene
mutants (e.g., lethal yellow Ay and viable yellow Avy) are dominant regulatory
mutations that cause the wild-type agouti protein to be produced abnormally
throughout all the body due to the control of the Raly promoter. This overexpression decreases the melanocortin signals inducing hyperphagia and obesity
(Hustad et al., 1995; Wisse et al., 2003). Heterozygotes (Ay/a) mice have ectopic
expression of agouti protein promoting pleiotropic phenotypes that include yellow
fur, hyperphagia (excessive hunger or increased appetite), and obesity with
increased adipose tissue mass accounting for 30-35% of total body weight after
the first few months. The Ay/a mice yellow fur phenotype is due to the inhibition
of α-MSH / adenylyl cyclase-induced eumelanin (brown-black pigment) synthesis
in hair follicular melanocytes by agouti protein leaving on the production of
phaeomelanin (yellow-red pigment) (Lu et al., 1994). Disruption of the
melanocortin signaling in the brain by the agouti protein is the principal cause of
hyperphagia and subsequently to obesity (Wisse et al., 2003). The Ay/a mouse
model recapitulates the human obesity phenotype and obesity-induced endocrine
profile (Fuentes-Mattei et al., 2014 In Press). Thus, heterozygous (Ay/a) are a
suitable obese mouse model to study the effect of obesity on pancreatic tumor 	
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1.4 Cancer metabolism
One of the emerging hallmarks of cancer cells is the changes in cell
metabolism (Hanahan and Weinberg, 2011) where mitochondrial oxidative
phosphorylation is switched to glycolysis. High expression of glucose transporter
1 (GLUT1) occurs in cancer cells (Reske et al., 1997), to internalize more
glucose used to compensate the energy production and high rate of glycolysis.
Lactate formation results from these metabolic changes (Ramanathan et al.,
2005). In addition, there are changes in gene expression as it occurs with the
up-regulation of transcription factors c-MYC and hypoxia inducible factor-1 (HIF1) (Altenberg and Greulich, 2004; Dang, 1999; Denko et al., 2003; Robey et al.,
2005) or down-regulation of p53 protein (Bensaad et al., 2006; Garber, 2006).
In pancreatic cancer, common genetic alterations include activation of the KRas (~90%) and loss of function of p53 tumor suppressor gene (50% to 75%)
(Hruban et al., 1999), both of which contribute to the glycolytic phenotype.
Expression of glycolytic enzymes is increased in pancreatic cancer compared
with paired noncancerous tissue (Mikuriya et al., 2007) and HIF-1α may mediate
trophic effects of insulin on pancreatic cancer (Wang et al., 2007). In the context
of DM2, activation of the protein kinase B (AKT)/ mammalian target of rapamycin
(mTOR)/HIF-1a pathway by insulin and/or IGF-1 (Scheid and Woodgett, 2001)
may also be driving the glycolytic phenotype to promote the survival of cancer
cells. Cancer cells use glucose to generate energy and phospho-metabolites to
drive cell division, growth, repair of DNA damage and drug detoxification
(Mazurek et al., 1997).
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There are several processes that may be promoting pancreatic cancer under
obese and DM2 conditions. Some of these factors are: high glucose, high
insulin, and hyper-activity of insulin-like-growth-factor-1 (IGF-1) (Li et al., 2009).
Different DM2 treatments have diverse mechanisms of action that will affect the
pancreatic cancer carcinogenesis.
Specific types of treatments for DM2 may have different impact on pancreatic
cancer based on their mechanisms of action, thereby having different outcomes
in terms of pancreatic cancer carcinogenesis and/or progression.
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1.5 Rationale and hypothesis
1.5.1

Significance and rationale

Pancreatic cancer is one of the most aggressive, with poor prognosis, lacking
effective diagnostic markers and therapies. Diabetes and obesity are modifiable
risk factors associated with accelerated pancreatic carcinogenesis and tumor
progression. However, the biological mechanisms by which diabetes and obesity
promote pancreatic cancer are not completely understood. The purpose of this
study is to demonstrate direct evidence for the mechanisms mediating these
epidemiologic phenomena. This research work shed a new insight of the
biological mechanism involved in the effects of obesity and diabetes on
pancreatic cancer aggressiveness. This research work also shed a new insight
on the effects of metformin and its potential as part of therapeutic interventions
for pancreatic cancer in obese patients.

1.5.2

Hypothesis

Obesity and DM2 accelerate pancreatic cancer and metformin treatment has
beneficial impact on primary prevention of pancreatic cancer.
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Chapter 2. Materials and methods
2.1 Chemical and reagents
Metformin (Enzo Life Sciences, Farmingdale, NY), was prepared at 400 mM
in distilled, deionized autoclaved water and filtered for sterile condition. Dilutions
were prepared in water or media depending on the experiment. Rosiglitazone
(Cayman Chemicals, Ann Arbor, MI) stock was prepared in Dimethyl sulfoxide
(DMSO) (Fisher, Pittsburg, PA) at a concentration of 100mM for each
experiment. D-Glucose, insulin, and methylthiazolydiphenyl-tetrazolium bromide
(MTT) were obtained from Sigma (St. Louis, MO).

2.2 Cell culture
2.2.1 Pancreatic cancer cells
MIA PaCa-2 and Panc-1, human pancreatic ductal adenocarcinoma cell lines
were obtained from American Type Culture Collection (ATCC; Manassas, VA).
PancO2, pancreatic ductal adenocarcinoma mouse cell line, was kindly provided
by Dr. Paul Chiao. This cell line was established from C57BL/6 mice in 1984
(Corbett et al., 1984). Cells were maintained in DMEM/F12 (Sigma, St. Louis,
MO) supplemented with 10% fetal bovine serum (FBS) (Gemini, West
Sacramento, CA) and 1% antibiotic/antimycotic solution (10,000 IU Penicillin (per
mL), 10,000ug/mL Streptomycin 25ug/mL Amphotericin) (Corning Life Sciences
Mediatech Inc, Manassas, VA). Cells were kept at 37oC in humid condition with
5% CO2.
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2.2.2 Differentiation of 3T3-L1 and co-culture conditions
Pre-adipocyte mouse fibroblast, 3T3-L1 were obtained from ATCC
(Manassas, VA) and kept in DMEM supplemented with 10% bovine calf serum.
Differentiated adipocytes were obtained by culture 3T3-L1 with differentiation
media containing 115 mg/mL methyliobutylxanthine, 10 µg/mL insulin, and 5 µM
dexamethasone for 48 hours. After 48 hours cells were culture with 10 µg/mL
insulin for 48 hours. Then, for 96 hours differentiated 3T3-L1 adipocyte cells
were kept in high glucose DMEM, 10% FBS to complete differentiation. The
3T3-L1 fibroblast cells were used only for up to 10 passages before
differentiation.
Transwell-clear permeable inserts of 0.4 µm pores (Corning Life Sciences
Mediatech Inc, Manassas, VA) were used to determine the effect of adipocytes
on pancreatic cancer migration. Adipocytes from 3T3-L1 were grown in 6-well
transwell plates and 25,000 PancO2 cells were seeded in the transwell Boyden
chamber (top). Cells that migrate through the membrane were determined by
crystal violet staining. PancO2 cells were co-cultured with matured adipocytes
for 72 hours. The cell number of PancO2 and adipocytes were determined by
counter coulter and PancO2 cell number was normalized to the number of
adipocytes. The cell viability was determined using Trypan blue (Sigma, Saint
Louis, MO) exclusion assay. Each treatment/condition was made in at least three
separate independent cell population (n=3) to allow for statistical evaluation.
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2.2.3 Media to mimic DM2 and obese conditions
In order to reproduce the glucose and insulin conditions found in diabetes
and obese patient, MIA PaCa-2 cells were cultured in different media to perform
MTT assays (Table 2.2.3). Normal condition media was prepared by adding
normal serum levels of glucose (100 mg/dL) and insulin (0.0005 mg/L). Diabetes
media contained high glucose and high insulin (400 mg/dL and 5 mg/L
respectively). Obese media had normal glucose (100 mg/dL), high insulin (5
mg/L) and leptin (6.24 nM).

Table 2.2.3: Conditioned media to mimic diabetes type 2 (DM2) and obese
situation.
Glucose
(mg/dL)

Insulin
(mg/L)

Leptin (nM)

Normal

100

0.0005

---

Diabetes Mellitus Type 2
(DM2)

400

5

---

Obese

100

5

6.24

DM2/Obese

400

5

6.24

Condition

2.3 Protein extractions and quantification
2.3.1 Cell harvesting for protein extraction
Cells were culture in 10 cm dishes or 6-wells, and treated for 24-72 hours as
indicated in the experiments. In order to collect all the cells, including those that
were loosely attached, cells were scrapped by using a cell lifter (Corning Life
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Sciences Inc, Manassas, VA) while still in the media. Then, cells were washed
twice with Phosphate buffer saline (PBS) and centrifuged at 1,400 rpm to remove
media and cell wastes. For the second wash cells were transferred to
microtubes and centrifuge in the microcentrifuge (Eppendorf, Hauppauge, NY).
Cell pellet were subjected to protein extraction or freeze at -80oC for further
processing. For protein extraction, cell pellets were lysed with 100-500 µL of
lysis buffer: 20 mM Tris-HCl pH 8.0 (Fisher, Pittsburg, PA), 100 mM NaCl
(Fisher, Pittsburg, PA), 1mM EDTA (Fisher, Pittsburg, PA), 0.1% Nonidet P-40
(USB Corp. Santa Clara, CA), 0.1% Triton X-100 (Sigma, Saint Louis, MO). The
following phosphatases and proteinases inhibitors were added to the lysis buffer
to prevent protein dephosphorylation and protein degradation: 1 mM sodium
orthovanadate, 1 mM sodium fluoride, 0.1 mg/ml Pepstatin A, 1 mM
phenylmethylsulfonyl fluoride, and a mixed of protease inhibitor cocktail (0.2
mg/mL aprotinin, 0.1 mg/mL antipain, 2 mg/mL soybean trypsin inhibitor, and 1
mg/mL leupeptin) (Sigma, Saint Louis, MO). Cells were incubated on ice with the
lysis buffer for 20 minutes and sonicated for 10 seconds to extract the cell
proteins. Centrifuged at 14,000 rpm in a refrigerated microcentrifuge during 20
minutes to precipitate cell debris. Protein extracts were collected and quantitated
for further analysis.

2.3.2 Tissue preparation for protein extraction
Snap frozen tumors were placed on dry ice, portions of the tumors were cut
and weighed to lyse. Tumors sections were placed into 5 mL tubes while kept on
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ice. To extract the proteins ice-cold lysis buffer (see section 2.3.1) was added to
each tumor in a ratio of 1 mL for each 40 mg of tumor. Tumors were
homogenized by using an electric homogenizer for 8 seconds. Homogenizer
probe was washed twice in between each sample. Tumors were incubated in
lysis buffer 10 minutes in ice and sonicated for 10 seconds. Then, cell lysates
were transferred to microtubes and centrifuged at 14,000 rpm at 4oC in a
microcentrifuge (Eppendorf, Hauppauge, NY) to precipitate the cell debris.
Supernatant fraction containing cell proteins were transferred to new microtube
and protein concentrations were determined.

2.3.3 Determining protein concentration
Protein concentrations were determined using the Protein Assay Dye
Reagent (Bio-Rad, Hercules, CA). A standard curve using Albumin Bovine
Serum (BSA) (Sigma, Saint Louis, MO) was used to calculate the concentration
of each sample. The optical density was read on Powerwave XS microplate
spectrophotometer (Biotek, Winooski, VT). Samples were prepared to have
equal amount of protein per volume (e.g. 1 µg/µL). Samples used for Western
Blot analysis were prepared by adding 5x sample buffer (100 mL: 3.78g Tris
base, 5.0g SDS, 25g sucrose, 0.04 g bromophenol blue, pH6.8) containing 5% of
2-mercaptoethanol (Sigma, Saint Louis, MO) and boil for 5 minutes to denature
the proteins and break disulfide bonds before loading into the polyacrylamide gel.
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2.3.4 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDSPAGE)
Polyacrylamide gels were prepared by using 30% Acrylamide/bis-acrylamide
solution (37.5:1 ratio) (Bio-Rad), gels could be stored at 4oC for up to one week
prior to loading the samples. The gels used for these experiments were between
8% to12% depending on the molecular weight of the protein to be detected.
After gel electrophoresis samples were wet transferred (transfer buffer: 25 mM
Tris base, 192mM Glycine, pH 8.2-8.4 with 20% methanol) to a polyvinylidine
fluoride (PVDF) (Millipore, Billerica, MA). Membranes were stained with
Ponceau S (Sigma) by incubating 5 minutes in a 0.1% Ponceau in 1% acetic acid
solution to detect protein transference. Membranes were subjected to Western
Blot analysis.

2.3.5 Western Blot analysis
PVDF membranes, obtained from the transference, were blocked according
to the antibodies of interest. For total protein detection, we used 5% non-fat milk
in Tris-Buffer saline (20 mM Tris-HCl, pH 7.5, 150 mM NaCl) with 0.1% Tween20 (Fisher) (TBS-T). Membranes designed for detection of phosphorylated
proteins were blocked with 5% BSA in TBS-T. Membranes blocking were
performed 1 hour at room temperature. Blocking solution was discard and
membranes were briefly washed with TBS-T. Incubation with primary antibodies
was at 4oC overnight. After primary antibody incubation membranes were
washed three times with TBS-T for 10-15 minutes each. Secondary antibody,
conjugated to horseradish peroxidase, incubation was performed at room
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temperature for 1 hour. Then, membranes were washed with TBS-T three times
for 10-15 minutes each, to remove any remaining antibody. For protein
detection, membranes were incubated with the Millipore Luminata Crescendo
chemiluminiscence substrate (Millipore) and detected by photographic film
(Denville Scientific, South Plainfield, NJ).
See Table 2.3.5 for antibody information.
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Table 2.3.5: Antibody List
Name

Source

Company

Actin

Rabbit

Annexin V-FITC

Mouse

Catalog
Number
A2066

mTOR

Rabbit

pAMPK (Thr172)
p70S6 Kinase
Phospho-p70S6 Kinase
(Thr389)
Tubulin
PTEN
AKT
Phospho-AKT (Ser473)

Rabbit
Rabbit

Sigma
BD
Biosciences
BD
Biosciences
Cell Signaling
Novus
Biologicals
Cell Signaling
Cell Signaling

Mouse

Cell Signaling

9206

Mouse
Rabbit
Rabbit
Rabbit
BD
Bioscience
Rabbit

Sigma
Cell Signaling
Cell Signaling
Cell Signaling
BD
Biosciences
Cell Signaling

T-5168
9552
9272
9271

Rabbit

Cell Signaling

4856

Rabbit

Cell Signaling

9452

Rabbit

Cell Signaling

9456

Rabbit

Cell Signaling

2971

Anti-poly (ADP ribose)
polymerase (PARP)
AMPK

Bcl-2
S6 ribosomal protein
Phospho-S6 Ribosomal
Protein (Ser235/236)
4E-BP1
Phospho-4E-BP1
(Ser65)
Phospho-mTOR
(Ser2448)

Mouse
Rabbit
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556419
551024
2532
28130002

2535
9202

610538
2217

2.4 Flow cytometry analysis
2.4.1 Apoptosis analysis
Cells were cultured in 6 well-plates and treated with the specified treatment
conditions. At the time of collecting the cells for apoptosis assay first we
collected the media, containing loosely attached cells, followed by trypsinization
and collection of attached cells. Together, cells were centrifuged at 1,400 rpm for
5 minutes and washed twice with PBS. Cells were resuspended in 500 µL of 1x
binding buffer, prepared fresh from the 10x Binding buffer (0.1 M HEPES, pH 7.4;
1.4 M NaCl; 25 mM CaCl 2) (Axxora Platform) and Annexin V (BD Biosciences,
San Jose, CA). Control cells without Annexin V were used on each experiment.
Incubation with Annexin V was performed at room temperature for 15 minutes
and samples were protected from light. Then, cells were washed twice with 1x
binding buffer. Propidium iodide (10 µL of the 50 µg/mL dilution) (Sigma) with
RNAse A (500 mg/ml, Roche) was added before doing the flow cytometry
analysis using the BD FACS Canto II (BD Biosciences, San Jose, CA). Cells
were divided between healthy population, necrotic cells, early apoptosis, and late
apoptosis.

2.4.2 PI staining
Cells were cultured in 6-wells plates. Appropriate treatments were applied
for 24-48 hours. Cells were washed with PBS and scrapped to detach and
transferred to a tube. After centrifugation, 500 µL of hypotonic propidium iodide
buffer (0.1% Sodium citrate (Sigma), 0.1% Triton X-100, 50 µg/mL Propidium
iodide, 0.5 mg/mL RNAse) were added to each sample and incubated for 30
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minutes protected from the light. Samples were place on ice and immediately
analyzed for cell cycle using a FACS Canto II flow cytometer (BD Biosciences,
San Diego, CA).

2.4.3 Cell sorting
Cells infected with FG12 vector containing GFP were expanded for cell
sorting. Cells were washed with PBS and trypsinized. The number of cells was
determined using the hemacytometer. After centrifugation, 10-20 million cells
were re-suspended in 1 mL of media, transferred to a Falcon tube with a cell
strainer cap (Corning Inc, Corning, NY) to separate into single cells. Cells were
sorted by GFP signal using the FACS Aria II (BD Biosciences, San Jose, CA).
Parental cells not infected with the Luciferase plasmid were used as control
(Figure 2.4.3). Cells were collected into media and eventually plated in to cell
culture dish.
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Figure 2.4.3: Green fluorescent protein (GFP) PancO2 cell sorting. PancO2
cells infected with lentivirus Luc-FG12 were sorted for GFP positive cells. Noninfected PancO2 cells (left panel) were used as control. The Luc-FG12
PancO2cells positive for GFP (right panel) were collected and plated to expand
for orthotopic syngeneic mice experiments.
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2.5 Time-lapse microscopy
For each experiments cells were treated as described. Cells were plated
to form a monolayer and kept in the incubator overnight. Cell wounds were
performed inside the biosafety cabinet by using a sterile tip. Then, culture media
was replace for the treatment media containing metformin (5 mM) or
rosiglitazone (100 µM). The microscope (Zeiss, Oberkochen, Germany) was set
to keep a temperature of 37oC and 5% CO2 in a humid environment. Axio Vision
Rel 4.6 software was used to set the parameters for the image capture. Several
images were taken from each treatment. For each well three different areas were
captured every 30 minutes for over 36 hours time period. A minimum of 3
biological replicas for each condition was performed. Wound gap was analyzed
using Image J (software from National Institute of Health, MA).

2.6 Proliferation assay
2.6.1 Cell counting
In order to determine the treatment effect on cell proliferation cells were
counted using a hemacytometer or using Z1 Coulter counter (Beckman Coulter,
Fullerton, CA). Cells were cultured in 6-well plates and treated for 24 hours after
plating. Treatments were performed for 24 to 48 hours in triplicates. Then, cells
were tripsinized and counted. Average cell numbers were plotted
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2.6.2 MTT assay
For proliferation assay cells were plated to obtain a confluence of 20% 24
hours after plating (between 2,500 to 10,000 cells depending on the cell type) in
96-well plates. Then, media was carefully aspirated and 200 µL of treatment
media (Table 2.2.3) were added. After 48 hours incubation 20 µL of 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) solution
were added, MTT assay (Feng et al., 2011). After 2 to 4 hours incubation, media
was aspirated and 200 µL of DMSO were added to solubilize the dye formed
from the MTT reaction. Plates were shake in a rotary mixer and the 570 nm
optical densitometry was measured in a plate spectrophotometer MRX revolution
(Dynex Technologies, Chantilly, VA) or Powerwave XS microplate
spectrophotometer (Biotek, Winooski, VT). Each condition had at least 4 replicas.
Statiscal analyses were performed using Sigma plot XXII software (Systat Inc.,
San Jose, CA). To determine the Inhibitory concentration (IC50) sigmoidal curve
fitting was used and one-way anova was used for comparison between multiple
groups.

2.7 Extracellular acidification rate (ECAR) and oxygen consumption rate
(OCR) levels using seahorse
Pancreatic cancer cells were cultured with their respectively treatments or
in co-culture with adipocytes. For treatments, cells were plated in the XF24
microplate (Seahorse, North Billerica, MA) and treated 24 hours before assay.
Cells co-cultured with adipocytes were tripsinized and plated in the XF24
microplate (Seahorse, North Billerica, MA) 8 hours before the assay to have a
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monolayer (20,000 cells/well). Low sodium bicarbonate assay Medium pH 7.4
(Seahorse, North Billerica, MA), was prepared the night before running the assay
by adding 1 mM sodium pyruvate, 1 mM glutamine, 25 mM D-glucose and placed
at 37oC. Cartridge was re-hydrated with assay buffer overnight and incubated in
a hypoxic incubator. Culture media was replaced for above mentioned low
sodium bicarbonate assay medium pH 7.4 and equilibrated 1 hour in a hypoxic
incubator at 37oC.
A series of mitochondrial inhibitors were used to determine the glycolysis
and mitochondrial respiration capacities of the cells after the treatments. In order
to inhibit the ATP synthase, 10 mM oligomycin (Sigma, Saint Louis, MO) were
added to determine mitochondrial independent oxygen consumption. To
determine the maximal respiration, 10 mM hydrophobic acid carbonylcyanide-4(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma, Saint Louis, MO), a proton
ionophore was used. Finally, a combination of 10 mM Rotenone (Sigma, Saint
Louis, MO) and Antinamycin A (Sigma, Saint Louis, MO), mitochondrial electron
transport inhibitors at complex I and III respectively, were used to determine the
spare respiratory capacity. Inhibitors were sequentially added to establish the
ECAR and OCR. Results were analyzed using Seahorse XF software
(Seahorse, North Billerica, MA). To normalize the results protein concentration
was determined.
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2.8 Glucose uptake
The fluorescent glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol- 4yl)amino)-2-deoxyglucose (2-NBDG), was used to determine its uptake into the
cells. Glucose free medium (Life Science Technology, Grand Island, NY)
containing 120 µM 2-NBDG and 10% FBS was used to replace the media the
day of the experiments. Images were taken with a fluorescent inverted
microscope (Nikon, Melville, NY) before media replacement, 15 minutes, 30
minutes, 1 hour, and 2 hours after 2-NBDG media was added. Fluorescent
microscopy images were taken using 488-wavelength filter. At the same time
points flow cytometry analysis to determine the percent of positive fluorescent
cells was performed, BD FACS Canto II (BD Biosciences, San Jose, CA).

2.9 Lentiviral infection
FG12 plasmid and virus packaging were kindly provided by Dr. Paul
Chiao. The FG12 plasmid was originally developed by Qin, X. F. et al. (Qin et al.,
2003) and it was modified to contain the luciferase promoter by Dr. Paul Chiao’s
laboratory (Figure 2.9) here on called Luc-FG12. Packaging vectors contain the
expression plasmid lentiviral vector vesicular stomatitis virus (VSV)- G, and two
HIV lentiviral packaging constructs pRSVREV and pMDLg/pRRE (Qin et al.,
2003). To produce the virus 293T cells were transfected with 10 µg of each
plasmid Luc-FG12 (containing GFP and luciferase), VSV- G, pRSVREV, and
pMDLg/pRRE using liposomes (Zou et al., 2002). Virus was collected 48 and 72
hours after transfection of 293T cells. Culture media from 293T cells was
collected and filtered by a 45 µm syringe filter. Then, 2 mL of fresh media and 8
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µg/mL of polybrene were added to the media containing the virus. Virus
containing media was used to infect PancO2 cells, which were plated the day of
the transfection into 6-well plates. After adding 2 mL of virus containing media to
each well cell plate was centrifuged at 1,800 rpm for 45 minutes. Plates were
incubated at 37oC and 5% CO2. Infection was repeated at 48 and 72 hours. To
confirm transfection, cells could be observed under the microscope to detect the
GFP. To select only those infected cells positive for GFP, flow cytometry
analysis cell sorting (See section 2.4.3 Cell Sorting). Sorted cells were expanded
and used for mice experiments.
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Figure 2.9: Lentiviral vector Luc-FG12. Relevant portions are shown in the
figure above. The vector contains the cytomegalovirus (CMV) promoter, the HIV
Flap element, the insertion site of Luciferase, and the EGFP sites. FG12 vector
(Qin et al., 2003) was developed from the FUGW (Lois et al., 2002) vector that
came from the human immunodeficiency virus-1 (HIV) lentiviral vector (Miyoshi et
al., 1998).
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2.10 Mouse Models
2.10.1 Nude Mice Xenograft
Nude mice were obtained from the Department of Experimental Radiation
Oncology at The University of Texas M. D. Anderson Cancer Center (Houston,
TX). Mice were maintained in barrier facility in compliance with all animal care
and use guidelines. All animal experiments were performed in accordance to M.
D. Anderson Institutional Animal Care and Use Committee (IACUC) and
approved by the American Association for Laboratory Animal Science (AALAS).
MIA PaCa-2 cells were injected in the flank of mice at a concentration of
500,000 cells in 200 µL of PBS. Metformin (1g/Kg/day) and rosiglitazone (1.5
mg/Kg/day) were provided in drinking water. Tumor growth were monitored
measuring with a caliper and tumor volume was estimated by: Length x Width2 /2
(Osborne et al., 1985). Mice were sacrificed before tumors reach the 1.5 cm
mean diameter. Tumors were collected and weighed. Tumors were collected for
protein extraction and immunohistochemistry (IHC) analysis.

2.10.2 Obese and Diabetic Mouse Models
Different strains of C57 B6 background mice, obtained from Jackson
laboratories (Bar Harbor, MN), were used to mimic obese and diabetic mouse
model conditions. Agouti gene mutant mice, Ay/a obese mouse model B6.CgAy/J stock: 000021 (Bar Harbor, MN). Leptin receptor heterozygous mutant
mouse model +/Leprdb mice strain: B6.Cg-m +/+ Leprdb/J; stock: 000697, was
obtained from Jackson Laboratories (Bar Harbor, MN). C57 BL/6J stock:000664
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wild type mice were used as breeders. Breeding pairs were obtained from
Jackson Laboratories and mice were bred in the institution animal facility
following the regulations. Obese mice Ay/a were crossed with C57BL/6J wild
type mice to obtain Ay/a mice, homozygous Ay mice are lethal. The yellow fur
identified Ay/a mice. Heterozygous leptin receptor mutant mice +/Leprdb were
crossed with itself to obtain Leprdb/Leprdb mice that are diabetic/obese mouse
model. To identify leptin receptor mutant mice, mouse genotyping were
performed. Wild type littermates were used as experimental controls. These
mice were used for the Orthotopic syngeneic mouse experiments. All animal
experiments were performed in accordance to M. D. Anderson Institutional
Animal Care and Use Committee and approved by the American Association for
Laboratory Animal Science (AALAS).

2.10.3 Mouse Genotyping
Leptin receptor db mutant mice were identified by genotyping. Briefly,
mice tails were clipped (0.5 cm) after 15 days old before weaning. Tail snips
were incubated with DNA extraction buffer (100 mM Tris pH8.0, 0.2% SDS, 5
mM EDTA, and 200 mM NaCl) containing 0.5 mg/mL Proteinase K overnight
(>16 hours) at 55oC. To extract the DNA samples were incubated 30 minutes at
room temperature with Phenol/chloroform. After centrifugation the soluble
fraction was transferred to a new tube and DNA was precipitated with 100%
Ethanol. DNA was washed with 70% ethanol and finally dissolved in
distilled/deionized autoclaved water.
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Mouse tales DNA were used to perform polymerase chain reaction (PCR)
for Leptin receptor. Primer sequences: 5' AGA ACG GAC ACT CTT TGA AGT
CTC 3' and 5' CAT TCA AAC CAT AGT TTA GGT TTG TGT 3' (Jackson
Labotratories, Bar Harbor, Maine) Tm 52oC. PCR products were digested with
Rsa I restriction enzyme, Rsa I recognize the leptin receptor point mutation (Fig.
2.10). 2% low-melting agarose gel was used to separate the bands to identify
wild-type, heterozygous and homozygous leptin receptor mice.
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Figure 2.10.3: Genotyping for Lepr PCR products digested with RsaI
restriction enzyme. 2% low melting agarose gel was used for detection of leptin
receptor gene single point mutation G to T that results in a stop codon. Mutant
leptin receptor was identified by PCR product digestion with the RsaI restriction
enzyme. Heterozygous female and male Leprdb/db mice show a 135 bp band
(wild type) and a 108 bp band (mutant). Wild type mice only show the 135 bp
band. Homozygous for the leptin receptor mutation show only a band at 108 bp
(data not shown). Mutant males show a nonspecific band above the 135 bp as
described by Jackson Laboratories.
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2.11 Pancreatic Cancer Orthotopic Syngeneic Mouse Model
Mouse treatment with metformin started two weeks prior to the surgery.
Metformin was provided by oral gavage at increasing doses starting at 50
mg/Kg/day until reach to 300 mg/Kg/day for Leprdb/Leprdb and 300 mg/Kg/day for
Ay/a mice. The Mice were prepared for surgery by shaving the left side of their
bodies prior to the surgery. Isofluorane (Fisher, Pittsburg, PA) was used to
anesthetize the mice to perform the surgery. PancO2 cells were prepared
200,000 cells in 30 µL Matrigel with reduced growth hormones (BD Bioscience,
San Jose, CA) and injected into the pancreas of the mice (Fig 2.11).
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Figure 2.11: Surgical procedure for PancO2 orthotopic syngeneic mouse
model. Mice were anesthesized using isofluorane (A), an incision was
performed in the left side of the mouse (B) to expose the pancreas for injection of
2 x 105 PancO2 cells with matrigel containing low growth factors in 30 µL total
volume (C-D). Pancreas was returned into the abdominal cavity and the wound
was sutured (E). Mice were observed for recovery.
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2.12 Oral Glucose Tolerance Test (OGTT)
Mouse glycemic status was established by oral glucose tolerance test
(OGTT) (Zhao et al., 2011). Mice were fasting for 16 hours previous to the
OGTT and blood glucose was measured previous to the glucose oral gavage
(1.5 g/Kg) and measured at 15, 30, 60, and 120 minutes after. Plot for the
glucose levels against time and the area of the curve were performed.

2.13 In vivo imaging
Tumor growth were monitored using Xenogen IVIS 100 (Perkin Elmer,
Waltham, MA). 150 mg/Kg D-luciferin (Perkin Elmer, Waltham, MA) were i.p.
injected into each mouse prior to the imaging. Images were captured 5, 10 and
15 minutes after D-luciferin injection.

2.14 Transcriptomic analysis
A portion of the orthotopic syngeneic pancreatic cancer tumors obtained at
the end point was used for total RNA extraction with TRIzol (Life Science
Technologies, Grand Island, NY). Gene expression analyses of the RNA
samples were performed at the Genomic Core Facility at The University of Texas
M. D. Anderson Cancer Center. Illumina MouseWG-6_V2_0_R3 (Illumina Inc,
Madison, WI) array platform was used to examine the transcriptomic profile of the
allografted PancO2 pancreatic tumor samples.
Data obtained from the gene array was analyzed using Nexus Expression
Analysis (BioDiscovery Inc., Hawthorne, CA). Those genes that were found to
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have significant difference (p<0.01) were further analyzed. Genes with changed
expression that was significant (P≤0.01, absolute value of log ratio >0.1, pool
size for intensity-based pooling 100,000) are presented as heat maps and also
are listed in Tables.

2.15 Metabolic analysis
Pancreatic tumors were collected from mice and 100 µg were snap frozen
for metabolomic analyses (Metabolon, Durham, NC).

Eight samples of each

group: control (lean), obese (Ay/a mouse), diabetic (Leprdb/Leprdb), Ay/a treated
with metformin, and Leprdb/Leprdb treated with metformin. Samples were
processed for Metabolon standard solvent extraction method. Then, samples
were divided in two parts for Gas chromatography/ Mass Spectrometry (GC/MS)
and liquid chromatography/MS/MS (LC/MS/MS). For pair-wise test Welch’s ttest and/or Wilcoxon’s rank sum test were used. For repeated measures Anova
analysis was used. For classification random forest analysis was performed.
Statistical analyses were performed with the program “R” http://cran.rproject.org/.

2.16 Multiplex analysis
Protein samples from allografted PancO2 tumors were used for multiplex
immuno-analysis (EMD Millipopre, Billerica, MA) to study the AKT/mTOR
pathway. Total and phosphorylated proteins were analyzed.
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Multiplex consist on the use of a unique combination of magnetic
microsphere covalently coupled to the antibody to capture the protein of interest.
A second biotinylated labeled antibody that detect the protein of interest in a
secondary site to make an immuno-sandwich.

These combinations of dyes

generate a unique fluorescent signature for each bead set.

Multiplex is

performed in 96-well plates using approximately 20 µg of protein per kit to detect
several target proteins in each sample. Magnetic beads are maintained in the
bottom of the plate using a magnet for at least 1 minute before changing the
different buffers and solutions. Streptavidin-Phycoerythrin (SA-PE) was used for
detection. Luminex 200 system (Luminex Corporation, Austin, TX) was used to
analyze the samples.

2.17 Statistical analysis
Sigma plot, software (Systat Inc., San Jose, CA) or GraphPad Prism
version 6 were utilized to perform statistical analyses. Different tests were used
along this project according to the experimental design. Student t-test or oneway Anova were used to establish statistical differences. Statistical difference
was considered if p≤ 0.05.
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Chapter 3. Results
3.1 Studying the role of glucose, insulin and adipocytes on pancreatic
cancer and the effect of anti-diabetic drugs.
3.1.1 Glucose, insulin and adipocytes cause cancer cell growth and
metabolic changes
High levels of glucose, high adipocyte content and insulin are some of the
characteristics of DM2. Therefore we study the effect of glucose, insulin and
adipocytes on pancreatic cancer cell growth.
Pancreatic cancer cells Panc-1 and MIA PaCa-2 were initially plated at
equal number with different concentrations of insulin and glucose and cultured for
72 hours. Live cells were measured by MTT assay measuring the optical density
(O.D. at 570 nm) (Figure 3.1.1-1). Insulin promotes cell proliferation. Glucose
effect on promoting cancer cell growth was markedly higher at low
concentrations of insulin. This phenomenon was also observed in breast cancer
cells (Figure A1).
To study the effect of adipocytes on pancreatic cancer cell growth we
used differentiated 3T3-L1 in co-culture. PancO2 mouse pancreatic cancer cell
line was culture with pre-adipocytes and adipocytes. After 72 hours of co-culture,
we found that adipocytes promote the proliferation of PancO2 cells (Figure 3.1.12).
MTT assays to compare proliferation between treatments with different
conditioned media, mimicking physiological normal, diabetes, obese, and
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diabetes/obesity situations (Figure 3.1.1-3). Different condition media were
prepared with varied concentrations of glucose, insulin and leptin levels as
described in Table 2.2.3, Materials and Methods section. Diabetes, obesity, and
DM2/obese conditioning media promoted the cell proliferation compared with
control.
Oxygen consumption rate (OCR) in MIA PaCa-2 cells is reduced by coculture with adipocytes. Moreover, OCR/Extracellular acidification rate
(OCR/ECAR) ratio is also decreased by co-culture with adipocytes (Figure 3.1.14).
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Figure 3.1.1-1. Pancreatic cancer cells proliferation is accelerated by
glucose and insulin. MTT assays to determine the proliferation of Panc-1 (left)
and MIA PaCa-2 (right), upon stimulation with different concentrations of insulin
and glucose. Different concentrations of insulin (0, 0.0005, 0.5 and 5 µg/L: xaxis) and glucose (500, 1,000, 2,000 and 4,000 mg/L: z-axis). O.D. 570 was
used to measure cell proliferation (y-axis). Reprinted with permission from Wiley
Online: Journal of Cellular and Molecular Medicine (Feng, Velazquez-Torres, et
al., 2011), copyright 2011.
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Figure 3.1.1-2: Co-culture of 3T3-L1 adipocytes promotes PancO2 cell
growth. 3T3-L1 were cultured and differentiated to adipocytes in the Boyden
chamber wells. PancO2 cells were seeded in the membrane and co-culture with
either pre-adipocytes or mature adipocytes for 72 hours. PancO2, pre-adipocyte
and adipocyte cells were tripsinized and counted. Adipocytes were used to
normalize based on the cell number. One-way Anova statistical analysis was
used. Error bars represent 95% confidence.
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Figure 3.1.1-3: Diabetes mellitus type 2 (DM2), Obese and DM2/Obese
media enhance pancreatic cancer cells proliferation. MIA PaCa-2 cells were
cultured for 72 hours in different condition media for DM2, obese and DM2/obese
media. One-way ANOVA statistical analysis shows significant differences
between normal condition media and all the conditions DM2, Obese and diabetic
of p<0.001.
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Figure 3.1.1-4: Adipocytes promote a shift in the glucose metabolism
toward aerobic glycolysis in pancreatic cancer cells. Oxygen Consumption
Rate/Extracellular Acidification Rate ratios of MiaPaCa2 cells (cultured alone or
co-cultured with pre-adipocytes or adipocytes) were determined at baseline and
upon sequential injection of Oligomycin, FCCP and Rotenone + Antimycin A.
Each treatment was repeated in 4 independent wells of XF96 microplate.
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3.1.2 Metformin and Rosiglitazone reduce cancer cells growth in vitro.
We have established the important role of diabetes and obesity in
pancreatic cancer cell growth, therefore we hypothesize that controlling glucose
levels may be beneficial. MIA PaCa-2 cells were cultured with different antidiabetic treatments (metformin, rosiglitazone and exenatide) and the anti-obesity
treatment orlistat. Result shows that metformin, rosiglitazone and orlistat
decrease the pancreatic cancer cell proliferation (Figure 3.1.2-1) under different
condition media: normal (Figure 3.1.2-1A), obese (Figure 3.1.2-1B), DM2 (Figure
3.1.2-1C) and DM2/obese (Figure 3.1.2-1D). Metformin did not have much effect
under normal condition media (Figure 3.1.2-1A) but it decreases proliferation
when cells are in obese (Figure 3.1.2-1B), DM2 (Figure 3.1.2-1C) and
DM2/obese (Figure 3.1.2-1D) media. Rosiglitazone and orlistat treatments were
effective under all the conditions (Figure 3.1.2-1A-D). Excenatide did not have
any effect on proliferation, probably due to its mechanism of action.
To further study the effect of metformin and rosiglitazone on proliferation
the number of viable cells after treatment was determine by cell counting. Both
treatments show statistical significant effect decreasing proliferation of MIA
PaCa-2 cells when compare with the control (Figure 3.1.2-2).
To study the effect of metformin on adipocytes-induced pancreatic cancer
cell proliferation we used the in vitro co-culture system to grow PancO2 cells with
3T3-L1 differentiated adipocytes. After 72 hours of treatment with metformin, our
results showed that metformin decreases adipocytes-induced pancreatic cancer
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cell proliferation significantly at concentrations of 0.5 mM and 1 mM (Figure
3.1.2-3).
Since we have found that metformin and rosiglitazone can reduce
proliferation of pancreatic cancer cells we investigated if these treatments affect
cell migration by doing wound-healing assay. Cell images were captured for 36
hours while incubated with treatments. Wound gap was almost completely closed
after 36 hours for Control (Figure 3.1.2-4 A left column) while the wounds of cells
with metformin and rosiglitazone treatments remain open (Figure 3.1.2-4 A
center and right column). Wound area was measured and plotted (Figure 3.1.2-4
B) showing that both treatments prevent the wound closure indicative of a
reduction in cell migration. In addition we tested metformin and rosiglitazone
effect on migration of breast (Her 18, Figure A.2) and ovarian (ES-2, Figure A.3)
cancer cell lines, where we observed similar results.
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Figure 3.1.2-1: MIA PaCa-2 proliferation is reduced by Metformin,
Rosiglitazone and Orlistat treatments. MIA PaCa-2 cells control or treated
with Metformin (20 mM), Rosiglitazone (100 µM), Orlistat (10 mM), and
Excenatide (250 µg/mL). Cells were cultured for 48 hours with the treatments in
different conditioning media normal (A), obese (B), DM2 (C) or DM2/Obese (D).
MTT assay were performed and plotted. Error bars are 95% confidence intervals.
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Figure 3.1.2-2: Rosiglitazone and Metformin treatments reduce MIA PaCa-2
cell growth. Trypan blue staining was used to determine the effect of Metformin
and Rosiglitazone on MIA PaCa-2 cells proliferation. Cells were culture 24 hours
with no drug (control), 100 µM Rosiglitazone or 20 mM Metformin. Results show
statistical significant difference between the groups tested by One-way ANOVA.
Error bars are 95% confidence.
Reprinted with permission from Wiley Online: Journal of Cellular and Molecular
Medicine (Feng, Velazquez-Torres et al., 2011), copyright 2011.
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Figure 3.1.2-3: Metformin reduced proliferation of PancO2 co-cultured with
3T3-L1 adipocytes. Boyden chamber co-culture system (0.4 µm membrane)
was used to determine the effect of Metformin in PancO2 proliferation when coculture with 3T3-L1. Equal number of PancO2 cells were co-culture with
differentiated 3T3-L1 adipocytes with Control (no treatment), 0.1 mM Metformin,
0.5 mM Metformin, and 1 mM Metformin for 72 hours. The graph shows the
proliferation of PancO2 cells normalized with the number of adipocytes. Oneway ANOVA statistic analysis was used to compare the groups. Error bars
represent 95% confidence.
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Figure 3.1.2-4: Metformin and Rosiglitazone inhibit migration of MIA PaCa-2
cells. MIA PaCa-2 cells were plated and incubated to form a monolayer. Then, a
wound (scratch) was performed and treatments were added. (A) Wound closure
was monitored by using time-lapse microscopy and images of MiaPaCa-2 cells
show the wound area over at different time points 0, 12, 24, and 36 hours.
(B) Plot of the quantitated wound area at different time points. Each treatment
was normalized with its time 0 hours (initial wound area).
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3.1.3 Metformin and Rosiglitazone Promote Apoptosis of Pancreatic
Cancer Cells
To study deeper the mechanism by which Metformin and Rosiglitazone
prevent pancreatic cancer cell proliferation and migration we analyze the drugs
effect on apoptosis. Indeed Metformin and Rosiglitazone increased cell
apoptosis analyzed using flow cytometry analysis for FITC-Annexin-V staining
(Figure 3.1.3-1). Results from flow cytometry analysis after PI staining of
PancO2 cells treated with Metformin or Pioglitazone (another type of
thiazolidinedione drug) show that SubG1 population is increased after treatment
(Table 3.1.3).
Western Blot analysis to detect apoptotic markers confirmed that
apoptosis treatement with metformin and rosiglitazone are causing apoptosis to
pancreatic cancer cells. PTEN tumor suppressor gene increases with
rosiglitazone and also decreases AKT (Ser473) phosphorylation (Figure 3.1.3-2).
Both metformin and rosiglitazone inhibit anti-apoptotic protein Bcl-2 and promote
PARP cleavage (85 KDa band) (Figure 3.1.3-2). Metformin cause
phosphorylation of AMPK (Thr172). To study the regulation of mTOR pathway
by these drugs we perform Western Blot analysis to determine phosphorylation
of mTOR and some of its downstream targets. Results showed that both drugs
decreased phosphorylation of mTOR (Ser2448) and its downstream target pS6
Ribosomal protein (Ser235/236) (Figure 3.1.2-3). For metformin we observed
that it also caused a decrease in the phosphorylation of p70S6 kinase (Thr 389)
and 4EBP1 (Ser65) (Figure 3.1.2-3). These results prove that metformin or
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rosiglitazone are causing cells death via apoptosis and regulate AKT/mTOR
signaling.
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Figure 3.1.3-1: Metformin and rosiglitazone induce apoptosis. MIA PaCa-2 cells
were treated with metformin (10 mM) or rosiglitazone (100 µM) for 48 hours. Cells
positive for FITC-Annexin-V were detected by flow cytometry analysis, (two right
quadrants of each graph) early and late apoptosis (also positive for PI staining). Reprinted
with permission from Wiley Online: Journal of Cellular and Molecular Medicine (Feng,
Velazquez-Torres, et al.2011), copyright 2011.
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Table 3.1.3: Metformin and Pioglitazone treatments increased PancO2 Sub
G1 population.
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Figure 3.1.3-2: Regulation of apoptotic proteins by rosiglitazone and
metformin treatments favoring cell death. Western Blots of MIA PaCa-2 cells
total protein extracts for PTEN, phospho-AKT (Ser 473), phospho-AMPK
(Thr172) and Bcl-2 all obtained from Cell Signaling Technologies (Danvers, MA),
PARP (BD Bioscience, San Jose, CA) and Tubulin (Sigma, Saint Louis, MO).
Reprinted with permission from Wiley Online: Journal of Cellular and Molecular
Medicine (Feng, Velazquez-Torres et al. 2011), copyright 2011.
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Figure 3.1.3-3: Inhibition of mTOR pathway by metformin and rosiglitazone
on pancreatic cancer cells. MIA PaCa-2 cells were treated with Metformin
(20mM) or Rosiglitazone (100 µM) for 48 hours. Western Blot analysis for total
mTOR (Novus Biologicals, Littleton, CO), phospho-mTOR, p70S6 Kinase, pS6
Ribosomal Protein, S6 ribosomal protein, phospho-4EBP1, and 4EBP1 (Cell
Signaling Technologies, Danvers, MA) and Tubulin (Sigma, Saint Louis, MO).
Reprinted with permission from Wiley Online: Journal of Cellular and Molecular
Medicine (Feng, Velazquez-Torres, et al. 2011), copyright 2011.
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3.1.4 Anti-diabetic drugs shift pancreatic cancer cells glucose uptake
and metabolic state
To test the effect of the anti-diabetic drugs (metformin and rosiglitazone) and
the anti-obesity drug (orlistat) on glucose uptake, 2-NBDG, a fluorescent glucose
analog (Life Science Technologies, Grand Island, NY), was used. Cells that had
glucose uptake were seen fluorescent (Figure 3.1.4-1, Top panel). In addition,
flow cytometry analysis was performed to quantitate the number of cells positive
for 2-NBDG (Figure 3.1.4-1, bottom panel). All the treatments showed decrease
glucose uptake when compare with control, non-treated, cells.
We proceed to measure the basal extracellular acidification rate (ECAR) in
cells treated with metformin, to understand the glycolytic flux. ECAR was less in
the metformin treated at 2.5 mM and 5.0 mM (Figure 3.1.4-2 top panel). In
addition to the ECAR we measure the basal oxygen consumption rate (OCR),
indicative of mitochondrial respiration, which was lower in the metformin treated
cells (Figure 3.1.4-2 bottom panel).
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Figure 3.1.4-1: Metformin, rosiglitazone and orlistat reduce glucose uptake
in pancreatic cancer cells. Representative Fluorescent images of MIA PaCa-2
cells taken at 0, 1 and 2 hours of 2-NBDG incubation for control or treatments,
metformin, rosiglitazone, metformin/rosiglitazone, orlistat, orlistat/metformin (top
panel). Flow cytometry analysis showing 2-NBDG uptake (bottom panel).

	
  

56	
  
	
  

Figure 3.1.4-2: Metformin shift the glycolytic flux and mitochondrial
respiration of MIA PaCa-2 cells. 2.5 and 5 mM Metformin shift the extracellular
acidification rate (ECAR) (top panel) and the oxygen consumption rate (OCR)
(bottom panel).
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3.1.5 Metformin and rosiglitazone decrease pancreatic cancer tumor growth
in an in vivo xenograft mouse model
To test the potential of metformin and rosiglitazone to inhibit the growth of
pancreatic cancer in vivo, nude mice xenograft mouse model was used. Mice
were subcutaneously injected with MIA PaCa-2 cells in the flanks. Metformin or
rosiglitazone treatments were provided into drinking water starting the day of the
injection. Twenty five days after injection mice were sacrificed by CO2
asphyxiation followed by cervical dislocation.
Representative mice and tumors from control, rosiglitazone and metformin
treatment are shown in Figure 3.1.4-1 panel A. Mice tumors were excised and
weighed. Tumor weight was plot against each treatment (Figure 3.1.4-1B).
Rosiglitazone and Metformin both show a decrease in the tumor weight but
metformin was the one with the largest change. Also metformin staining of Ki-67
shows a decrease in staining when compare for control (Figure 3.1.4-2 top row).
There was no difference in the caspase-3 staining between the groups (Figure
3.1.4-2 bottom row).
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Figure 3.1.5-1: Tumor mass in MIA PaCa-2 cell is decreased with
rosiglitazone and metformin treatments. (A) Representative mice from
control, rosiglitazone treated, metformin treated (top panel) and their resected
tumors (bottom panel). (B) Tumor mass were plotted for each treatment, each
group n=5. Error bars represent 95% confidence.
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Figure 3.1.5-2: Immunohistochemistry (IHC) analysis of MIA PaCa-2 tumor
xenograft.
Tumors from MIA PaCa-2 cells xenograft were analyzed by IHC. Ki-67 and
caspase-3 staining.
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3.2 Study of the role of obesity and diabetes in pancreatic cancer
3.2.1 Orthotopic syngeneic mouse models to study in vivo obesity and
diabetes effects on pancreatic cancer
In order to further understand the impact of obesity and DM2 in pancreatic
cancer we employed both obese and diabetic orthotopic/syngeneic allograft
mouse models. Oral glucose tolerance test was performed to characterize the
glucose tolerance status on each mouse model (Figure 3.2.1-1A and 3.2.1-2A).
Our obese mouse model phenocopy the human mild glucose intolerance caused
by obesity, while our diabetic mouse model shows severe glucose intolerance
(Figure 3.2.1-1B and 3.2.1-2B). Our observations show that these effects on
glucose tolerance were suppressed by two-weeks treatment with metformin
(300mg/Kg/day) Ay/a (Figure 3.2.1-1). We used in vivo tumor bioluminescence
imaging from allografted PancO2-Luc-FG12 to access the effect of obesity and
DM2 on pancreatic tumor growth. Weekly bioluminescence imaging of the mice
were performed to monitor tumor growth. Our results show that in both obese
(Ay/a) and diabetic (Leprdb/db) allografted-tumor growth is significantly accelerated
(Figure 3.2.1-3 and 3.2.1-4). Whereas, treatment with metformin decreases
pancreatic tumor growth in both mouse models (Figure 3.2.1-3 and 3.2.1-4).
Measurements of allografted tumor weight confirm our in vivo imaging findings
(Figure 3.2.1-3C). Comparison of tumors weigh showed significant increase in
tumor weigh of the non-treated obese mice when compare with the wild type
mice and a significant reduction in tumor weight was found when compare with
the obese metformin treated. Protein and phospho-protein levels analyses of
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allografted revealed that both obesity and obesity/DM2 in vivo environment
induce activation of AKT/mTOR signaling pathway protein members (Figure
3.2.1-5A and 3.2.1-6A). We found that treatment with metformin can revert this
effect (Figure 3.2.1-5B and 3.2.1-6B).
Transcriptomic analysis of the allografted pancreatic cancer tumors
showed that tumors from obese mice had significantly increased expression of
342 genes and significantly decreased expression of 568 genes compared with
those from lean littermate mice (Figure 3.2.1-7). Allografted pancreatic cancer
tumors from diabetic mice had significantly increased expression of 2078 genes
and significantly decreased expression of 3937 genes compared with those from
non-diabetic lean littermate mice (Figure 3.2.1-9). Metformin treatment showed
that tumors from treated obese mice had significantly increased expression of
157 genes and significantly decreased expression of 282 genes compared with
those from non-treated obese mice (Figure 3.2.1-7). Metformin-treated diabetic
mice had significantly increased expression of 218 genes and significantly
decreased expression of 172 genes compared with those from non-treated
diabetic mice (Figure 3.2.1-9).
We used Nexus Expression 3 software to perform unsupervised functional
transcriptomic analysis. This analysis identified 29 biological processes that were
significantly different (P<0.01) between the obese and non-obese mice (Table
3.2.1-1), and 17 biological processes between the obese /DM2 and non-diabetic
mice (Table 3.2.1-3). We also identified 30 biological processes that were
significantly different (P<0.01) between the metformin-treated obese and non-
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treated obese mice (Table 3.2.1-2), and 76 biological processes between the
metformin-treated diabetic and non-treated diabetic mice (Table 3.2.1-4). Using
gene set enrichment analysis (GSEA) (Subramanian et al., 2005), which is
considered more supervised and specific transcriptomic analysis, we showed
significant upregulation of protein kinase B (AKT) target genes, genes involve in
the glucose metabolism, and genes involve in the epithelial-mesenchymal
transition (EMT) in allografted pancreatic tumors from both mouse models
(Figure 3.2.1-8 and figure 3.2.1-10). Thus, our data suggests that obesity and
obesity/diabetic in vivo environment promote tumor growth and aggressiveness
via the AKT/mTOR signaling pathway and by promoting transcriptional changes
enhancing glucose metabolism and a more invasive phenotype.
In order to investigate the metabolomic changes induced by obesity and
diabetes, we sent the allografted pancreatic tumor samples for metabolomic
analysis. Global biochemical profiling of allografted tumor tissues revealed a
large number of differences that were observed in both obese and diabetic
mouse models, as compared to control littermates. Metabolomic results showed
113 metabolites that were significantly different (P<0.05) between the obese and
non-obese mice, and 117 metabolites significantly different between the obese
/DM2 and non-diabetic mice (Figure 3.2.1-11 and Figure 3.2.1-12). Most of
these differences are associated with lipid metabolism, amino acids, dipeptides,
nucleotides metabolism and oxidative stress.
Levels of long chain free fatty acids (FFA), including the essential fatty
acids linoleate and linolenate, were significantly elevated in allografted tumors
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from both obese and diabetic mouse models, relative to control littermates. In
addition to FFA, monoacylglycerols were increased significantly in tumors from
obese mice. Moreover, tumors from obese mice showed significant increase in 3hydroxybutryate (BHBA) and trending increases in acetyl-carnitine. In addition to
changes in lipid metabolism, glucose and fructose levels were elevated in tumors
from diabetic mice. Tumors from both obese and diabetic mice showed
significantly low levels of glucose-6-phosphate and fructose-6-phosphate, while
3-phosphoglycerate and phosphoenolpyruvate (PEP) were elevated with no
difference in lactate levels in comparison to control littermates. Metformin
treatment slightly increased in glucose-6-phosphate, fructose-6-phosphate, and
PEP, while significantly increased levels of several sugar alcohols (e.g., galactitol
and xylitol), N-acetylneuraminate, and mannose-6-phosphate in tumor from from
both obese and diabetic mice.
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Figure 3.2.1-1: Metformin decreases obesity-induced mild glucose
intolerance in obese orthotopic/syngeneic pancreatic cancer mouse model.
(A) Oral glucose tolerance tests (OGTT) of obese (B6;Ay/a, n=12) and lean
(B6;a/a, n=9) littermate mice. Error bars represent 95% confidence intervals.
(B) Oral glucose tolerance tests (OGTT) of obese (B6;Ay/a, n=11) and metformintreated (300mg/Kg/day) obese (B6;Ay/a - Metformin, n=9) after two weeks of
treatment. Error bars represent 95% confidence intervals.
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Figure 3.2.1-2: Metformin decreases diabetes-induced glucose intolerance
in diabetic orthotopic/syngeneic pancreatic cancer mouse model. (A) Oral
glucose tolerance tests (OGTT) of diabetic (B6;Leprdb/db, n=10) and lean
(B6;Lepr+/+, n=4) littermate mice. Error bars represent 95% confidence intervals.
(B) Oral glucose tolerance tests (OGTT) of diabetic (B6;Leprdb/db, n=4) and
metformin-treated (300mg/Kg/day) diabetic mice (B6;Leprdb/db - Metformin, n=4)
after two weeks of treatment. Error bars represent 95% confidence intervals.
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Figure 3.2.1-3: Metformin decreases obesity-induced orthotopic/syngeneic
pancreatic tumor allograft growth. (A) Bar graph of the relative
bioluminescence intensity generated by the tumor of randomized B6;a/a (lean,
n=13), B6;Ay/a (obese, n=13), and metformin-treated obese (n=8) mice injected
into the pancreas body with pancreatic cancer after two week of treatment. (B)
Representative in vivo imagings of tumors’ bioluminescence performed 3-week
after orthotopic/syngeneic injection. (C) Representative images of syngeneic
allografted tumors harvested from randomized lean, obese, and metformintreated obese female mice (left panel, scale bars represent 5 mm). A bar graph
illustrates the mean tumor weights (right panel; n≥5 mice per group). Error bars
in panels A and C represent 95% confidence intervals.
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Figure 3.2.1-4: Metformin decreases diabetes-induced orthotopic/syngeneic
pancreatic tumor allograft growth. (A) Bar graph of the relative
bioluminescence intensity generated by the tumor of randomized B6;Lepr+/+
(lean, n=6), B6;Leprdb/db (diabetic, n=5), and metformin-treated B6;Leprdb/db (n=5)
mice injected into the pancreas body with pancreatic cancer after two week of
treatment. Error bars represent 95% confidence intervals. (B) Representative in
vivo imaging of tumors’ bioluminescence performed 3-week after
orthotopic/syngeneic injection.
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Figure 3.2.1-5: Metformin decreases obesity-induced activation of
AKT/mTOR signaling pathway in orthotopic/syngeneic pancreatic tumor
allografts.
(A) Phospho-protein levels of members of the Akt/mTOR signaling pathway from
syngeneic allografted tumor lysates from obese (B6;Ay/a, n=4) mice plotted
relative to those from lean mice (B6;a/a, n=4). (B) Phospho-protein levels of
members of the AKT/mTOR signaling pathway from syngeneic allografted tumor
lysates from metformin-treated obese mice (B6;Ay/a - Metformin, n=4) plotted
relative to those from obese mice (B6;Ay/a, n=4). Error bars represent 95%
confidence intervals.
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Figure 3.2.1-6: Metformin decreases diabetes-induced activation of
AKT/mTOR signaling pathway in orthotopic/syngeneic pancreatic tumor
allografts.
(A) Phospho-protein levels of members of the Akt/mTOR signaling pathway from
syngeneic allografted tumor lysates from diabetic (B6;Leprdb/db, n=4) mice plotted
relative to those from non-diabetic lean mice (B6;Lepr+/+, n=4). (B) Phosphoprotein levels of members of the AKT/mTOR signaling pathway from syngeneic
allografted tumor lysates from metformin-treated diabetic mice (B6;Leprdb/db Metformin, n=4) plotted relative to those from diabetic mice (B6;Leprdb/db, n=4).
Error bars represent 95% confidence intervals.
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Figure 3.2.1-7
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Figure 3.2.1-7: Transcriptomic changes associated with obesity and
metformin treatment in orthotopic/syngeneic pancreatic tumor allografts.
Heat map of the gene-probes significantly changed (p≤0.01, absolute value of log
ratio >0.1, pool size for intensity-based pooling 100,000; identified by Nexus
Expression software) in pancreatic tumor allografts from obese mice (B6;Ay/a,
n=5) and metformin-treated obese mice (B6;Ay/a - Metformin, n=4) relative to
those from lean littermate mice (B6;a/a, n=5).
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Table 3.2.1-1: Biological processes significantly (P<0.05) changed in
orthotopic/syngeneic pancreatic tumor allografts from obese compared
with non-obese mice identified by Nexus Expression.
BIOLOGICAL PROCESS

SCORE

P-VALUE

antigen receptor-mediated signaling pathway

-1.674291143

0.001937984

-1.589172

0.00204499

-1.592165906

0.002079002

CTP biosynthesis

1.562645101

0.003992016

GTP biosynthesis

1.562645101

0.003992016

UTP biosynthesis

1.562645101

0.003992016

regulation of balance

1.464688487

0.01039501

regulation of cytokine biosynthesis

-1.523279242

0.014084507

L-phenylalanine catabolism

-1.595330852

0.01511879

1.628073818

0.016326531

-1.5470298

0.020964361

-1.541536515

0.023206751

purine nucleotide biosynthesis

1.555811852

0.024122807

negative regulation of translation

-1.597175314

0.026156942

synaptogenesis

-1.513086526

0.027659574

1.42049563

0.029880478

-1.406220147

0.030425963

1.450249763

0.034764826

response to pheromone

-1.375537775

0.034836066

phospholipid metabolism

-1.695367327

0.036363636

regulation of neuronal synaptic plasticity

-1.556929042

0.041666667

-1.42955195

0.042471042

male sex determination
positive regulation of protein kinase activity

zinc ion transport
protein-chromophore linkage
positive regulation of B cell differentiation

embryonic development
neurotransmitter secretion
protein homotetramerization

lipid catabolism

	
  

73	
  
	
  

motor axon guidance

1.495323573

0.042735043

-1.439473425

0.044624746

protein metabolism

1.472455261

0.047058824

B cell proliferation

-1.525351343

0.047520661

regulation of embryonic development

-1.449610805

0.049079755

brown fat cell differentiation

-1.512420027

0.049462366

cortical actin cytoskeleton organization and
biogenesis

-1.500347696

0.049689441

metabotropic glutamate receptor signaling
pathway
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Table 3.2.1-2: Biological processes significantly (P<0.05) changed in
orthotopic/syngeneic pancreatic tumor allografts from metformin-treated
obese compared with obese mice identified by Nexus Expression.
BIOLOGICAL PROCESS

SCORE

nerve-nerve synaptic transmission

-1.888074216

0

-1.83675073

0

-1.692701962

0

negative regulation of immune response

1.592019747

0

determination of adult life span

1.556203985 0.002053388

retinol metabolism

1.598047026 0.004056795

apoptotic mitochondrial changes

1.736510417 0.005847953

acyl-CoA metabolism
pathogenesis

peptidyl-tyrosine phosphorylation

P-VALUE

-1.615307463

0.006

inactivation of MAPK activity

1.812358097

0.00804829

protein export from nucleus

1.638087376 0.011235955

membrane protein ectodomain proteolysis
negative regulation of endothelial cell
proliferation

-1.637538491 0.013861386
1.535684452 0.013916501

histidine catabolism

-1.508614122

0.02016129

lysosome organization and biogenesis

1.253259938 0.023404255

response to stress

1.576056745 0.026915114

translation

1.591697195 0.027777778

cell proliferation

1.370079768 0.030674847

actin filament-based movement

1.470453563 0.030737705

cell migration

-1.639441954 0.031311155

protein kinase C activation

1.574812075

regulation of balance

1.482277402 0.033126294

monoamine transport

-1.510035928 0.036585366

	
  

75	
  
	
  

0.032

response to heat

1.504802915 0.037623762

amino acid transport

-1.57012118 0.037924152

triacylglycerol metabolism

1.507384466 0.043396226

isotype switching

1.437620693 0.044921875

monovalent inorganic cation transport

-1.467085774 0.046601942

release of cytochrome c from mitochondria

1.497734491

osteoclast differentiation

1.542993892 0.048484848

positive regulation of axon extension

1.456913489 0.049309665
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0.04743833

Figure 3.2.1-8: Gene Set Enrichment Analysis of orthotopic/syngeneic
pancreatic tumor allografts transcriptomic profiles from obese and
metformin-treated obese mice.
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Figure 3.2.1-8: Gene Set Enrichment Analysis of orthotopic/syngeneic
pancreatic tumor allografts transcriptomic profiles from obese and
metformin-treated obese mice.
Gene Set Enrichment Analyses (GSEA) of transcriptomic profile from obese mice
(left panels) and metformin-treated obese mice (right panel) relative to their
control littermate mice. GSEA were for (A) AKT activation target genes, (B)
genes involve in the glucose metabolism, and (C) genes involve in the epithelialmesenchymal transition (EMT) and metastasis. Each bar corresponds to one
gene.
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Figure 3.2.1-9
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Figure 3.2.1-9: Transcriptomic changes associated with diabetes and
metformin treatment in orthotopic/syngeneic pancreatic tumor allografts.
Heat map of the gene-probes significantly changed (p≤0.01, absolute value of log
ratio >0.1, pool size for intensity-based pooling 100,000; identified by Nexus
Expression software) in pancreatic tumor allografts from diabetic mice
(B6;Leprdb/db, n=4) and metformin-treated diabetic mice (B6;Leprdb/db - Metformin,
n=4) relative to those from non-diabetic lean littermate mice (B6;Lepr+/+, n=5).
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Table 3.2.1-3: Biological processes significantly (P<0.05) changed in
orthotopic/syngeneic pancreatic tumor allografts from diabetic mice
compared with non-diabetic mice identified by Nexus Expression.
BIOLOGICAL PROCESS

SCORE

actin cytoskeleton organization and biogenesis
gamma-aminobutyric acid signaling pathway
cell redox homeostasis

P-VALUE

1.477698164 0.016483516
-1.689808152 0.017509728
1.498312572 0.017509728

protein-chromophore linkage

-1.543916303

0.01863354

phosphorylation

1.529232379

0.01875

tricarboxylic acid cycle

1.570427574 0.018907563

Mo-molybdopterin cofactor biosynthesis

1.450729032 0.031936128

ubiquitin-dependent protein catabolism

1.458953173 0.034615385

purine nucleotide biosynthesis

1.599643861 0.036538462

proton transport

1.41897114 0.037280702

axon guidance

-1.418488144

0.03815261

protein homotetramerization

1.382782216 0.040152964

cell motility

1.521752194 0.042635659

cobalt ion transport

-1.454758732 0.045833333

ovulation (sensu Mammalia)

-1.570571153

tetrahydrobiopterin biosynthesis

0.04743083

1.523609736 0.048300537

copper ion transport

1.49906061 0.049212598

calcium-dependent cell-cell adhesion

-1.391442349 0.049242424
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Table 3.2.1-4: Biological processes significantly (P<0.05) changed in
orthotopic /syngeneic pancreatic tumor allografts from metformin-treated
diabetic mice compared with diabetic mice identified by Nexus Expression.
BIOLOGICAL PROCESS

SCORE

cytoskeleton organization and biogenesis

-1.474161038 0.021543986

microtubule-based movement

-1.393981536 0.022556391

embryonic development (sensu Mammalia)

-1.370492704

0.02259887

negative regulation of protein kinase activity

-1.278196419

0.02259887

actin cytoskeleton organization and
biogenesis
innate immune response

P-VALUE

-1.374793819 0.022944551
1.59139184 0.023076923

nitrogen compound metabolism

-1.577897779 0.023121387

axon guidance

1.836990889 0.023166023

fatty acid desaturation

-1.682510548 0.023210832

negative regulation of cell differentiation
negative regulation of myeloid cell
differentiation
cell glucose homeostasis

-1.639949091 0.023210832

protein polymerization

-1.683135887 0.023300971

transcription initiation

1.432132918 0.023300971

-1.454776683 0.023255814
2.028564801 0.023300971

negative regulation of fibroblast proliferation

-1.429501064 0.023575639

regulation of cholesterol absorption

-1.176428311 0.023668639

natural killer cell differentiation

-1.628094531 0.023715415

regulation of cytokine biosynthesis

-1.524173487 0.023762376

ovulation (sensu Mammalia)

1.643051453 0.023904382

embryonic pattern specification

-1.648132032 0.023952096

fatty acid metabolism

-1.378046378

T cell receptor signaling pathway

0.024

1.840245041 0.024048096
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proteoglycan biosynthesis

-1.409921279 0.024096386

embryonic limb morphogenesis

-1.777445325 0.024144869

mitotic chromosome condensation

-1.441479318 0.024144869

melanocyte differentiation

-1.568416412 0.024291498

excretion

1.479631366 0.024439919

embryonic cleavage

1.590083363 0.024489796

frizzled-2 signaling pathway

-1.632673267 0.024539877

urogenital system development

-1.608792927 0.024590164

positive regulation of progression through
mitotic cell cycle

-1.582991585 0.024590164

calcium-independent cell-cell adhesion

-1.480983697 0.024691358

N-acetylglucosamine metabolism

1.603911761 0.024742268

one-carbon compound metabolism

-1.478395123 0.025052192

defense response

1.549819808 0.025477707

cartilage condensation

-1.474291437 0.025586354

retrograde axon cargo transport

1.505437065 0.025641026

immune response

1.644866022 0.026548673

inner ear morphogenesis

1.393060666 0.035643564

sulfate transport

1.595707293

melanin biosynthesis from tyrosine

1.559171666 0.045634921

lipid metabolism

-1.35343213 0.046678636

sexual reproduction

0.04494382

1.36838016 0.047244094

MAPKKK cascade

-1.270455816 0.048689139

nerve growth factor receptor signaling
pathway

-1.490130948 0.048828125

organic anion transport

1.377971903 0.049701789
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Figure 3.2.1-10: Gene Set Enrichment Analysis of orthotopic/syngeneic
pancreatic tumor allografts transcriptomic profiles from diabetic and
metformin-treated diabetic mice.
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Figure 3.2.1-10: Gene Set Enrichment Analysis of orthotopic/syngeneic
pancreatic tumor allografts transcriptomic profiles from diabetic and
metformin-treated diabetic mice.
Gene Set Enrichment Analyses (GSEA) of transcriptomic profile from diabetic
mice (left panels) and metformin-treated diabetic mice (right panel) relative to
their control littermate mice. GSEA were for (A) AKT activation target genes, (B)
genes involve in the glucose metabolism, and (C) genes involve in the epithelialmesenchymal transition (EMT) and metastasis. Each bar corresponds to one
gene.

	
  

85	
  
	
  

Figure 3.2.1-11: Metabolomic changes associated with obesity, diabetic and
metformin treatment in orthtopic/syngeneic pancreatic tumor allografts.
Heat map of the metabolic molecules (metabolites) significantly changed
(p≤0.05) in pancreatic tumor allografts from obese mice (B6;Ay/a, n=8) and
diabetic mice (B6;Leprdb/db, n=8) relative to those from lean littermate mice
(B6;a/a, n=8), metformin-treated obese mice (B6;Ay/a - Metformin, n=8) relative to
those from obese mice, and metformin-treated diabetic mice (B6;Leprdb/db Metformin, n=8) relative to those from diabetic mice.
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Figure 3.2.1-12: Venn diagram of metabolomic profile of pancreatic tumor
tissue allografts from orthtopic/syngeneic mouse models.
Venn diagrams of metabolites with significant changed levels from metabolomic
data. Metabolites with significant changed levels from obese mice and diabetic
mice relative to those from lean littermate mice (upper panel). Metabolites with
significant changed levels from obese mice and diabetic mice relative to those
from lean littermate mice (upper panel) metformin-treated obese mice relative to
those from obese mice, and metformin-treated diabetic mice relative to those
from diabetic mice.
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Chapter 4. Discussion
Many epidemiological studies have suggested the role of obesity and
diabetes in pancreatic cancer. We used a unique strategy to unveil the impact of
obesity and diabetes on pancreatic cancer growth. In this work we have in vitro
and in vivo approaches to better understand the relationship between these three
conditions.
We used different condition media to test different concentrations of
glucose and insulin in cell culture. We found that insulin promotes pancreatic
and breast cancer cells proliferation (Figures 3.1.1-1 and A1). The results
indicate that insulin and glucose promote cancer cell growth, but glucose effect is
insulin-dependent. Using the in vitro adipocyte system of 3T3-L1 fibroblast
differentiation, we were able to test the effect of adipocytes on pancreatic cancer
cell proliferation. PancO2 cells when co-cultured with adipocytes show a
significant proliferation (Figure 3.1.1-2). Moreover, we prepared different
conditioned media to mimic the diabetes (high glucose and high insulin) and
obesity (normal glucose, high insulin and high leptin) situations in the body. We
were able to observe significant changes between the different conditioned
media and the normal condition. This is a simplified conditioned media but we
were able to detect significant changes in the cell proliferation indicative of the
importance of glucose, insulin and adipokines in cancer cell growth. To further
evaluate the role of adipocytes on the pancreatic cancer cell metabolism we used
the co-culture system followed by seahorse analysis and found that metformin
shift the glucose metabolism toward aerobic glycolysis.

	
  

88	
  
	
  

As previously described about 80% of the pancreatic cancer patients has
diabetes (Permert et al., 1993). We have demonstrated that insulin, a basic
treatment for type 2 diabetes, have proliferative effect on pancreatic and breast
cancer. Our hypothesis is that some treatments for DM2 and obesity may have
beneficial impact in pancreatic cancer. We have found that some anti-diabetic
treatments, particularly metformin may be beneficial for treatments of pancreatic
cancer patients with obesity or diabetes.
Proliferation analyses using different conditioned media (normal, DM2,
Obese, and DM2/Obese) show that some drug treatments can reduce the cancer
growth, with only 48 hours cell treatment (Figure 3.1.2-1). Interestingly, we found
that metformin, rosiglitazone and orlistat had anti-proliferative effect on cancer
cell growth. We did not observe any effect with excenatide treatment, probably
at a systemic level would have a different outcome. In fact, we have shown the
beneficial impact of excenatide to overcome the dexamethasone induced
glucose intolerance in mice (Zhao et al., 2011). Metformin has been described to
be weight neutral or to cause weight-loss (Pi-Sunyer, 2008) so we tested its
effect when cells are treated in the presence of adipocytes. Indeed we observe a
significant decrease in cell proliferation. To study the impact of metformin and
rosiglitazone on cell migration we perform wound-healing assay and found that
these drugs also affect the cell migratory potential (Figures 3.1.2-4, A2 and A3).
Upon investigating the effect of the anti-diabetic treatments on cancer growth and
migration we continue studying the apoptotic potential of these drugs. We
observed that both metformin and rosiglitazone/pioglitazone were able to double
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the number of apoptotic cells as seen in the Annexin-V/PI staining and the subG1 population (Figures 3.1.1-1 and Table 3.1.3). To better understand the
impact of metformin and rosiglitazone on apoptosis we analyzed the protein
status of BCL-2 and PARP, apoptosis related proteins. The levels of cleaved
PARP were induced by both metformin and rosiglitazone indicative of apoptosis.
Furthermore the levels of the anti-apoptotic protein BCL-2 were reduced mainly
in the metformin treatment. All these findings indicate that metformin and
thiazolidinediones are capable to reduce cell proliferation and migration partly
because their ability to induce cell death through apoptosis.
For additional information on the function of metformin and rosiglitazone in
inhibiting pancreatic cancer cell proliferation we analyze protein levels of
AKT/mTOR pathway. Rosiglitazone decreases phosphorylation of AKT (Ser 473)
(Figure 3.1.3-2), mTOR (Ser 2448), and S6 ribosomal protein (Ser235/236)
(Figure 3.1.3-3). Metfomin decreases phosphorylation of mTOR (Ser 2448), S6
S6 ribosomal protein (Ser235/236), and 4EBP1 (Ser65). These findings indicate
that both metformin and rosiglitazone decrease the activity of the AKT/mTOR
pathway, which is affecting protein synthesis and cell growth.
Because glucose promotes the cancer cell proliferation we tested the
effect of metformin, rosiglitazone and orlistat in glucose uptake and found that all
of them reduced the glucose uptake in the MIA PaCa-2 cells. This result could
be indicative of a switch in metabolism caused by these drugs. As it has been
define by Otto Warburg cancer cells relies in glycolysis (Garber, 2006; Yeung et
al., 2008), and our results indicate that metformin and rosiglitazone are affecting
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the glucose uptake of the cancer cells. Also, we tested that metformin had an
effect on shifting the glycolytic flux and the mitochondrial respiration.
In addition to metformin, here we tested other treatments (rosiglitazone,
orlistat) that seem to have beneficial impact on preventing pancreatic cancer cell
proliferation. Although Rosiglitazone has been withdrawn from the market
because of its cardiotoxic effects, the use of pioglitazone, another
thiazolidinediones drug may be useful for treatment of diabetes in pancreatic
cancer patients. Orlistat was recently approved by FDA (Alli) to use for weight
loss and based on our in vitro results this may be a promising treatment for
adjuvant treatment of cancer patients, especially for those obese or diabetes
patients. In terms of excenatide we did not observed any effect in the in vitro
experiments but it is possible that in vivo use will have a different outcome.
Thus, metformin and rosiglitazone promoted apoptosis in cancer cells and
potentiated the apoptotic effect via AMPK and PTEN respectively, both regulating
the AKT/mTOR signalling pathway.
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Figure 4-1: Possible mechanisms of action of metformin and rosiglitazone
in pancreatic cancer cells. Adapted with permission from Wiley Online: Journal
of Cellular and Molecular Medicine (Feng, Velazquez-Torres, et al., 2011),
copyright 2011.
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Our orthotopic/syngeneic in vivo models recapitulates the increased
caloric intake that eventually promotes the development of obesity and diabetes
in humans. In this way we were able to study the obesity-related and diabeticrelated biological changes that are promoting pancreatic tumor growth and
overall pancreatic cancer aggressiveness. Here we integrated high-throughput
screening (e.g., transcriptomics and metabolomics), of tumors from our in vivo
models to determine and validate the biological mechanisms involved in obesityaccelerated and DM2-accelerated pancreatic cancer.
The elevated levels of long chain free fatty acids (FFA) in tumors from
both obese and diabetic mice reflect increased circulating levels of FFA and
triglycerides as a result of increased food consumption, fatty acid synthesis, and
mobilization of fat. Concurrent to this increase in FFA, transcriptomic analysis
showed decrease in genes related to lipid catabolism (e.g., Oc90, Pla2g10) in
tumors from obese or diabetic mice. Such increases in available fatty acids for
uptake may provide pancreatic tumors a significant growth advantage as many
cancers up-regulate fatty acid synthesis to support membrane synthesis (Currie
et al., 2013). Although Metformin treatment reduced tumor growth in the obese
and diabetic mice, the levels of FFA in these tumors were not altered in
comparison to untreated tumors. Metformin is known to inhibit fatty acid
synthesis by promoting inhibitory-phosphorylation of acetyl-CoA carboxylase
(Cantoria et al., 2014). Thus, obesity-induced and DM2-induced increase of FFA
in tumors is due to an increase in FFA intake by tumor cells. Fatty acid
catabolism, however, did appear to be increased in metformin-treated obese
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mice as indicated by a significant increase in 3-hydroxybutryate (BHBA) levels
and trending increases in acetylcarnitine, which is an indicator of acetyl-CoA, and
propionylcarnitine, which are a product of odd-chain fatty acid oxidation as well
as branched chain amino acid catabolism. Increased β-oxidation in metformintreated obese mice is consistent with the activation of AMPK by metformin
treatment (Pernicova and Korbonits, 2014; Zhou et al., 2001). These effects
appeared specific to obese mice.
Glucose and fructose levels were elevated in tumors from DB mice,
consistent with hyperglycermia. In tumors from both obese and diabetic mice,
the 6-carbon glycolytic intermediates glucose-6-phosphate and fructose-6phosphate were significantly lower, while the downstream 3-carbon intermediates
3-phosphoglycerate and phosphoenolpyruvate (PEP) were elevated, as
compared to control littermates. Although lactate levels were not different
between the groups, these changes are suggestive of decreased utilization of
glucose in tumors from either obese or diabetic mice coupled with supply of
downstream glycolytic intermediates from the catabolism of amino acids, such as
serine and alanine. As a result of some variabilty, several changes were
observed that were not statistically significant upon comparison tumors from
metformin-treated and non-treated mice, but yet the observations were
consistent with Metformin action. For example, glucose and fructose levels were
non-significantly reduced in tumors from metformin-treated diabetic mice as
compared to non-treated diabetic mice. In addition, a slight increase in glucose6-phosphate, fructose-6-phosphate, and PEP were observed in tumors from
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either obese or diabetic mice, as compared to the appropriate non-treated
controls. Together with significantly increased levels of several sugar alcohols
(e.g., galactitol and xylitol), N-acetylneuraminate, and mannose-6-phosphate in
tumors from treated obese or diabetic mice, these trends in glycolytic
intermediates suggest that metformin treatment increased glucose utilization by
multiple pathways in pancreatic tumors.
Transcriptomic enrichment analysis showed that tumors from obese or
diabetic mice have significant induction of expression of many genes related to
nucleotide biosynthesis. In contrast, the metabolomic analysis showed the purine
catabolites (e.g., xanthosine, xanthine, and urate) were significantly increased in
tumors from diabetic mice with metformin treatment. In tumors from obese mice,
we found significant and trending increased levels of urate and the pyrimidine
catabolite β-alanine, respectively, upon comparison of treated tumors to nontreated tumors. These changes are indicative of increased nucleic acid turnover
and production of H2O2 by xanthine oxidase, which may contribute to inhibition of
tumor growth associated with metformin treatment.
We have developed a feasible way to study the implications of obesity,
diabetes, and pancreatic cancer. Our animal models provide strong evidence for
the causal relationship between obesity, diabetes and accelerated pancreatic
cancers. Using this model we confirm that obesity and diabetes promotes the
progression of pancreatic cancer and the anti-diabetic drug metformin decreases
this progression. This study shed a new insight of the effects of metformin and
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its potential as part of therapeutic interventions for pancreatic cancer in obese
and diabetic patients.
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Chapter 5. Appendix
Appendix A
Cancer cell proliferation promoted by insulin and glucose.

A.1 Breast cancer cells, MCF7 and Her18, proliferation is accelerated by
glucose and insulin. MTT assays to determine the proliferation of MCF7 (left)
and Her18 upon stimulation with different concentrations of insulin and glucose.
We used different concentrations of insulin (0, 0.0005, 0.5 and 5 µg/L: x-axis)
and glucose (500, 1,000, 2,000 and 4,000 mg/L: z-axis). O.D. 570 was used to
measure cell proliferation. Reprinted with permission from Wiley Online: Journal
of Cellular and Molecular Medicine (Feng, Velazquez-Torres, et al., 2011),
copyright 2011.
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A.2 Metformin and Rosiglitazone inhibit migration of Her18 cells. A) Timelapse images of Her18 cells show the wound area over at different time points 0,
12, 24, and 36 hours. B) Quantification of the wound area at different time points.
Each treatment was normalized with its time 0 hours (beginning wound area).
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A.3 Metformin and Rosiglitazone inhibit migration of ES-2 cells. A) Timelapse images of ES-2 cells show the wound area over at different time points 0,
12, 24, and 36 hours. B) Quantification of the wound area at different time points.
Each treatment was normalized with its time 0 hours (beginning wound area).
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Figure 3.1.3-1: Metformin and rosiglitazone result in programed cell death,
apoptosis. Her18 cells were treated with metformin (10 mM) or rosiglitazone
(100 µM) for 48 hours. Cells positive for FITC-Annexin-V were detected by flow
cytometry analysis, (two right quadrants of each graph) early and late apoptosis
(also positive for PI staining). Reprinted with permission from Wiley Online:
Journal of Cellular and Molecular Medicine (Feng, Velazquez-Torres, et al.2011),
copyright 2011.
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